Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213934 · ClinicalTrials.gov registry record · Phase 1
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
A Phase 1 study, sponsored by University of Cincinnati.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07213934 is a Phase 1 study that is actively recruiting participants, run by University of Cincinnati. The registered enrollment target is 40 participants.
The verdict
NCT07213934, a Phase 1 study, is actively recruiting participants, sponsored by University of Cincinnati.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the Phase I study is to see if it is safe to use X-ray photon radiation (XRT) and proton radiation (PT) before surgery in patients with recurrent head and neck squamous cell carcinoma (rHNSCC). The purpose of the Phase II study is to see if using XRT or PT before immunotherapy (pembrolizumab) prior to surgery benefits patients with recurrent head and neck squamous cell carcinoma (rHNSCC).
Interventions
- DRUG Pembrolizumab
- RADIATION Proton therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07213934
The ClinicalTrials.gov registry entry for NCT07213934 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07213934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07213934 about?
NCT07213934 is a clinical study titled "Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma". The purpose of the Phase I study is to see if it is safe to use X-ray photon radiation (XRT) and proton radiation (PT) before surgery in patients with recurrent head and neck squamous cell carcinoma (rHNSCC). The purpose of the Phase II study is to see if using XRT or PT before immunotherapy (pembr...
What is the current status of trial NCT07213934?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-10-08. Estimated completion is 2031-12.
What interventions are being tested in trial NCT07213934?
The interventions under investigation include: Pembrolizumab (DRUG), Proton therapy (RADIATION).
Who is sponsoring clinical trial NCT07213934?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.